Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Three RNAi-Related Patent Applications: Oct 11, 2007

Title: Methods for Directing DNA Methylation in Mammalian Cells Using Homologous, Short Double-Stranded RNAs
Number: 20070231907
Filed: May 29, 2007
Lead Inventor: John Rossi, City of Hope
“The invention provides methods for methylating a gene of interest in a cell,” the patent application’s abstract states. “The methods include exposing a mammalian cell to an siRNA molecule which is specific for a gene of interest in the cell. The methods also include introducing into the cell DNA sequences encoding a sense strand and an antisense strand of an siRNA which is specific for the gene of interest. The siRNA directs methylation of the gene of interest.”

Title: C-Met siRNA Adenovirus Vectors Inhibit Cancer Cell Growth, Invasion, and Tumorigenicity
Number: 20070232555
Filed: March 28, 2005 PCT Filed: March 28, 2005
Lead Inventor: Nariyoshi Shinomiya, Van Andel Research Institute
“Suppression of the hepatocyte growth factor/scatter factor-Met signaling pathway by targeting the Met protein tyrosine kinase was tested as strategy for suppressing tumor growth,” the patent application’s abstract states. “Using RNA interference technology and adenoviruses carrying siRNA target sequences … Met expression in mouse, dog, and human tumor cells [was] ... dramatically reduced.”
The abstract adds that “Met was suppressed using Ad Met siRNA in mouse mammary tumor cells and Met-transformed cells, as well as human prostate cancer, sarcoma, glioblastoma, gastric, and ovarian cancer cells. Furthermore, the Ad Met siRNA infection reversed transformed cell morphology. Ad Met siRNA killed cancer cells by inducing apoptosis. RNAi targeting Met suppressed HGF/SF-mediated scattering as well as ligand-mediated invasion activity and growth of tumor cells,” it notes. “Met siRNA infection also abrogated downstream Met signaling to molecules such as Akt and p44/42 MAPK. Importantly, the Met siRNA triggered apoptosis was correlated to suppressed tumorigenicity in vivo. Intro-tumoral infection with c-met siRNA adenovirus vectors produced significant reduction in tumor growth.”

Title: siRNA Targeting Cell Division Cycle-Like 5
Number: 20070232797
Filed: April 9, 2007
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CDC2L5.”          

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.